Puma Biotechnology (PBYI) stock
Market cap $504M
Market closed. Prices as of Friday's close.
Follow PBYI's trial news. Members get an alert when Puma Biotechnology files news, and see its trials, share raises, and its CEO's filings.
What's next for PBYI
From Puma Biotechnology’s SEC filings and ClinicalTrials.gov: the company’s own words and the registry’s dates, not a forecast. Companies often miss their own dates.
Next step the company has named
For members: 3 trials underway and 23 filings.
For members: their 3 filings and quotes, and an alert each time they file.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why PBYI scores 16
ExcellentTrending up, 7 of 13 possible checks firingWhat the Quality Score means
Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.
- +7Momentum traits 7 firing right now, of 13 possible, one point each
- +4Long-term trend above a rising 200-day, near its 52-week high, at a multi-year high
- Run-up adds
- Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
- Persistence adds
No effect today: Size, Growth, Dilution, Volatility, Cash flow, and News.
Price, score, traits, and the industry rank are from a snapshot taken at 6:04 PM ET, at least 15 minutes behind. How we rank stocks.
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed +2.5% on average, higher 3 of 4 times.
What would move PBYI's score: 3 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
PBYI has 7 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How PBYI ranks in Biotech
PBYI is #8 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
- 1
TGTXTG Therapeutics8/1319
- 2
RGENRepligen7/1319
- 3
HALOHalozyme Therapeutics7/1319
EXELExelixisOpen for its score
ONCBeOne MedicinesOpen for its score
- 8
PBYIPuma Biotechnology7/1316
When does PBYI report, and what happens after?
Expected to report Thu Nov 5, after the close (in 39 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +0.4% | +9.7% | +7.3% |
| May 7, 2026After close | After close | -1.2% | +3.2% | -1.0% |
| Feb 26, 2026After close | After close | -17.1% | -25.0% | -18.0% |
| Nov 6, 2025After close | After close | +8.8% | +22.2% | +1.0% |
The gap is the next open against the close before the report; the reaction is where that session closed. PBYI closed higher after 3 of its last 4. Past behavior, not a forecast.
Report dates and past reactions come from sessions that have already closed, so none of these figures move.
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of PBYI's score, with the points and the reason
- All 14 checks on PBYI and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on PBYI
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.
The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.